Neuland Laboratories share news and announcements
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Last close ₹18,865.00down ₹70.00 (0.37%)BSE ₹18,924.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹18,935.00.
52-week range of traded prices to 23 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹24,204 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 48.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 May 2026
- 12.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.18%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 12 May 2026
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 53,34748.3% delivered
Neuland Laboratories share news and announcements
836 announcements, routine notices left out, newest first. Page 15 of 17.
May 2014
9 May · Dividend
Board of Directors of the Company at its meeting held on May 09, 2014 have recommended payment of dividend of 30% (including a special dividend of 15%) at Rs.3 per equity share on a face value of Rs.10 each, subject to the approval of members of the Company.
Apr 2014
Mar 2014
20 Mar · Management
Board of Directors had at its meeting held on March 20, 2014 approved re-appointment of Dr.D.R.Rao as the Chairman and Managing Director of the Company, for a further period of 5 years w.e.f. April 01, 2014 subject to the approval of the shareholders.
Feb 2014
5 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 05, 2014, inter alia, approved the following :(a) Issue of equity shares on Rights basis to the members of the Company not exceeding Rs.25 crores. (b) Constitution of a sub-committee called the Rights Issue Committee to finalize the Rights ratio, issue price, record date and all other matters relating the proposed Rights Issue.
Jan 2014
24 Jan · Board meeting
Inter alia, to consider and take on record the unaudited financial results of the Company for the quarter ended December 31, 2013. Further, as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from January 21, 2014 to February 06, 2014 (both days inclusive), inter alia, for the purpose of announcement of the Unaudited Financial Results by the Company.21 Jan · Business
Board of Directors of the Company on January 21, 2014, had allotted 10,700 fully paid up equity shares of a face value of Rs. 10 each, to eligible employees pursuant to exercise of stock options granted under Employee Stock Option Scheme, 2008. Consequently w.e.f. January 21, 2014, the paid-up equity capital of the Company stands increased to Rs. 7,65,56,780 from Rs. 7,64,49,780.
Nov 2013
Oct 2013
29 Oct · Board meeting
Inter-alia to consider and take on record the unaudited financial results of the Company for the quarter ended September 30, 2013.
Aug 2013
Jul 2013
22 Jul · Board meeting
Inter-alia, to consider and take on record the unaudited financial results of the Company for the quarter ended June 30, 2013.18 Jul · Legal
Price movement : Significant price movement has been observed in Neuland Laboratories Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Neuland Laboratories Limited has vide its letter inter-alia stated, " We would like to clarify that there is no such information withheld by the Company, which is price sensitive in nature and required to be disclosed to the Stock Exchanges as on date."
Jun 2013
27 Jun · Corporate action
Company has fixed Book Closure from July 26, 2013 to August 2, 2013 for the purpose of dividend and Annual General Meeting of the Company to be held on August 02, 2013.
May 2013
10 May · Dividend
Board of Directors of the Company at its meeting held on May 10, 2013 has recommended payment of dividend of Rs. 1.20 per share of a face value of Rs.10 each, subject to the approval of Bankers and shareholders of the Company.10 May · Management
Board of Directors of the Company at its meeting held on May 10, 2013 has approved reappointment of Mr. D. Sucheth Rao, as the Whole Time Director and Chief Executive Officer of the Company for a period of (5) Five years with effect from August 1, 2013, subject to the approval of shareholders in ensuing Annual General Meeting.2 May · Board meeting
Inter-alia to consider and take on record the audited financial results of the Company for the year ended March 31, 2013 and to consider and recommend dividend, if any.
Mar 2013
Feb 2013
Dec 2012
5 Dec · Updates
Pursuant to the acquisition of shares of the Company by Neuland Health Sciences Pvt. Ltd. (NHS) from the Promoters of the Company through inter-se transfer of shares amongst the Promoter group through off-market, the shareholding of NHS in the Company has gone up to 50.05%. Consequently, in terms of section 4(1)(b)(ii) of the Companies Act, 1956, the Company, has become a subsidiary Company of NHS.
Nov 2012
Oct 2012
29 Oct · Board meeting
Inter-alia to consider the unaudited financial results of the Company for the quarter ended September 30, 2012.
Sep 2012